In the ongoing battle against type 2 diabetes, a silent revolution is taking place—and it’s being driven by Dipeptidyl Peptidase-4 (DPP-4) inhibitors. This class of oral hypoglycemics is quickly rising to prominence as a go-to treatment option, and the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market is surging with remarkable momentum. According to recent industry...